Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for unresectable primary and metastatic liver tumors

World Journal of Surgical Oncology

Sadik Bilgic²  Elgin Ozkan¹  Seda Lacin¹  Cigdem Soydal¹  Ozlem N Kucuk¹ 

[1] Department of Nuclear Medicine, Faculty of Medicine, Ankara University, Ankara, Turkey;Department of Radiology, Faculty of Medicine, Ankara University, Ankara, Turkey

关键词: survival times;    liver tumors;    Selective intraarterial radionuclide therapy (SIRT);   

Others  :  1206679
DOI  :  10.1186/1477-7819-9-86

 received in 2011-02-11, accepted in 2011-08-06,  发布年份 2011

【 摘 要 】

Background

The aim of this study was to evaluate the success of selective intraarterial radionuclide therapy (SIRT) with Yttrium-90 (Y-90) microspheres in liver metastases of different tumors. We also interpreted the contribution of SIRT to survival times according to responder- non responder and hepatic- extra hepatic disease.

Methods

The clinical and follow-up data of 124 patients who were referred to our department for SIRT between June 2006 and October 2010 were evaluated retrospectively. SIRT has been applied to 78 patients who were suitable for treatment. All the patients had primary liver tumor or unresectable liver metastasis of different malignancies. The treatment was repeated at least one more time in 5 patients to the same or other lobes. Metabolic treatment response evaluated by fluorine-18 fluorodeoxyglucose (F18-FDG) positron emission tomography/computed tomography (PET/CT) in the 6^th week after treatment. F18-FDG PET/CT was repeated in per six weeks periods. The response criterion had been described as at least 20% decrease of SUV value. Also in patients with neuroendocrine tumor serial Gallium-68 (Ga-68) PET/CT was used for evaluation of response. Patients were divided into 2 groups according to their treatment response.

Results

68 patients received treatment for the right lobe, seven patients received treatment for the left lobe and 3 patients for both lobes. The mean treatment dose was estimated at 1.62 GBq. In the evaluation of treatment response; 43(55%) patients were responder (R) and 35 (45%) patients were non-responder (NR) in the sixth week F18-FDG PET/CT. Mean pretreatment SUVmax value of R group was 11.6 and NR group was 10.7. While only 11 (31%) out of 35 NR patients had H disease, 30 (69%) out of 43 R patients had H disease (p < 0.05). The mean overall survival time of R group was calculated as 25.63 ± 1.52 months and NR group's 20.45 ± 2.11 (p = 0.04). The mean overall survival time of H group was computed as 25.66 ± 1.52 months and EH group's 20.76 ± 1.97 (p = 0.09).

Conclusions

SIRT is a useful treatment method which can contribute to the lengthening of survival times in patients with primary or metastatic unresectable liver malignancies. Also F18-FDG PET/CT is seen to be a successful imaging method in evaluating treatment response for predicting survival times in this patient group.

【 授权许可】

   
2011 Kucuk et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, Gebski V: Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001, 12(12):1711-20.
• [2]Stubbs RS, Wickremesekera SK: Selective internal radiation therapy (SIRT): a new modality for treating patients with colorectal liver metastases. HPB (Oxford) 2004, 6(3):133-9.
• [3]Herba MJ, Thirlwell MP: Radioembolization for hepatic metastases. Semin Oncol 2002, 29(2):152-9.
• [4]Houle S, Yip TK, Shepherd FA, Rotstein LE, Sniderman KW, Theis E, Cawthorn RH, Richmond-Cox K: Hepatocellular carcinoma: pilot trial of treatment with Y-90 microspheres. Radiology 1989, 172(3):857-60.
• [5]Lau WY, Ho S, Leung TW, Chan M, Ho R, Johnson PJ, Li AK: Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 1998, 40(3):583-92.
• [6]Blanchard RJ, Morrow IM, Sutherland JB: Treatment of liver tumors with yttrium-90 microspheres alone. Can Assoc Radiol J 1989, 40(4):206-10.
• [7]Yan ZP, Lin G, Zhao HY, Dong YH: An experimental study and clinical pilot trials on yttrium-90 glass microspheres through the hepatic artery for treatment of primary liver cancer. Cancer 1993, 72(11):3210-5.
• [8]Bienert M, McCook B, Carr BI, Geller DA, Sheetz M, Tutor C, Amesur N, Avril N: 90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT. Eur J Nucl Med Mol Imaging 2005, 32(7):778-87. Epub 2005 Mar 17
• [9]Vente MA, Wondergem M, van der Tweel I, van den Bosch MA, Zonnenberg BA, Lam MG, van Het Schip AD, Nijsen JF: Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol 2009, 19(4):951-9. Epub 2008 Nov 7
• [10]Szyszko T, Al-Nahhas A, Canelo R, Habib N, Jiao L, Wasan H, Pagou M, Tait P: Assesment of response to treatment of unresectable liver tumours with Y-90 microspheres: value of FDG PET versus computed tomography. Nucl Med Comm 2007, 28:15-20.
• [11]Wong CY, Gates VL, Tang B, Campbell J, Qing F, Lewandowski RJ, Thie J, Ho CL, Savin M, Salem R: Fluoro-2-Deoxy-D-Glucose positron emission tomography/Computed tomography predicts extrahepatic metastatic potential of colorectal metastasis: a practical guide for yttrium-90 microsphere liver-directed theraphy. Cancer Bioth and Radioph 2010, 25:233-236.
• [12]Stubbs RS, Cannan RJ, Mitchell AW: Selective internal radiation therapy (SIRT) with 90Yttrium microspheres for extensive colorectal liver metastases. Hepatogastroenterology 2001, 48(38):333-7.
• [13]Van Hazel G, Blackwell A, Anderson J, Price D, Moroz P, Bower G, Cardaci G, Gray B: Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 2004, 88(2):78-85.
• [14]Murthy R, Xiong H, Nunez R, Cohen AC, Barron B, Szklaruk J, Madoff DC, Gupta S, Wallace MJ, Ahrar K, Hicks ME: Yttrium 90 resin mircospeheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. J Vasc Interv Radiol 2005, 16:937-945.
• [15]Stubbs R, O'Brien I, Correia M: Selective internal radiation therapy with 90Y spheres with colorectal liver metastases: singe-cetre experience with 100 patients. ANZJ Surg 2006, 79:696-703.
• [16]Anderson JH, Goldberg JA, Bessent RG, Kerr DJ, McKillop JH, Stewart I, Cooke TG, McArdle CS: Glass yttrium-90 microspheres for patients with colorectal liver metastases. Radiother Oncol 1992, 25:137-139.
• [17]Andrews JC, Walker SC, Ackermann RJ, Cotton LA, Ensminger WD, Shapiro B: Hepatic radioembolization with yttrium-90 containing glass micro-spheres: preliminary results and clinical follow-up. J Nucl Med 1994, 35:1637-1644.
• [18]Sato KT, Lewandowski RJ, Mulcahy MF, Atassi B, Ryu RK, Gates VL, Nemcek AA Jr, Barakat O, Benson A, Mandal R, Talamonti M, Wong CY, Miller FH, Newman SB, Shaw JM, Thurston KG, Omary RA, Salem R: Unresectable chemorefractory liver metastases: radioembolization with Y-90 microspheres-safety, efficacy and survival. Radiol 2008, 248:507-515.
• [19]Bujold A, Dawson LA: Stereotactic radiation therapy and selective internal radiation therapy for hepatocellular carcinoma. Cancer Radiother 2011, 15(1):54-63. Epub 2011 Jan 15
• [20]Kennedy AS, Salem R: Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies. Cancer J 2010, 16(2):163-75. Review